Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 3/2017

01-03-2017 | Original Article

High target attainment for β-lactam antibiotics in intensive care unit patients when actual minimum inhibitory concentrations are applied

Authors: H. Woksepp, A. Hällgren, S. Borgström, F. Kullberg, A. Wimmerstedt, A. Oscarsson, P. Nordlund, M-L. Lindholm, J. Bonnedahl, L. Brudin, B. Carlsson, T. Schön

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 3/2017

Login to get access

Abstract

Patients in the intensive care unit (ICU) are at risk for suboptimal levels of β-lactam antibiotics, possibly leading to poor efficacy. Our aim was to investigate whether the actual minimum inhibitory concentration (MIC) compared to the more commonly used arbitrary epidemiological cut-off values (ECOFFs) would affect target attainment in ICU patients on empirical treatment with broad-spectrum β-lactam antibiotics and to identify risk factors for not reaching target. In a prospective, multicenter study, ICU patients ≥18 years old and treated with piperacillin/tazobactam, meropenem, or cefotaxime were included. Clinical and laboratory data were recorded. Serum trough antibiotic levels from three consecutive days were analyzed by liquid chromatography–mass spectrometry (LC-MS). The target was defined as the free trough concentration above the MIC (100% fT>MIC). MICECOFF was used as the target and, when available, the actual MIC (MICACTUAL) was applied. The median age of the patients was 70 years old, 52% (58/111) were males, and the median estimated glomerular filtration rate (eGFR) was 48.0 mL/min/1.73 m2. The rate of patients reaching 100% fT > MICACTUAL was higher (89%, 31/35) compared to the same patients using MICECOFF (60%, p = 0.002). In total, 55% (61/111) reached 100% fT > MICECOFF. Increased renal clearance was independently associated to not reaching 100% fT > MICECOFF. On repeated sampling, >77% of patients had stable serum drug levels around the MICECOFF. Serum concentrations of β-lactam antibiotics vary extensively between ICU patients. The rate of patients not reaching target was markedly lower for the actual MIC than when the arbitrary MIC based on the ECOFF was used, which is important to consider in future studies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Emmerson M (2000) Antibiotic usage and prescribing policies in the intensive care unit. Intensive Care Med 26(Suppl 1):S26–S30CrossRefPubMed Emmerson M (2000) Antibiotic usage and prescribing policies in the intensive care unit. Intensive Care Med 26(Suppl 1):S26–S30CrossRefPubMed
2.
go back to reference Thomas Z, Bandali F, Sankaranarayanan J, Reardon T, Olsen KM; Critical Care Pharmacotherapy Trials Network (2015) A multicenter evaluation of prolonged empiric antibiotic therapy in adult ICUs in the United States. Crit Care Med 43:2527–2534CrossRefPubMed Thomas Z, Bandali F, Sankaranarayanan J, Reardon T, Olsen KM; Critical Care Pharmacotherapy Trials Network (2015) A multicenter evaluation of prolonged empiric antibiotic therapy in adult ICUs in the United States. Crit Care Med 43:2527–2534CrossRefPubMed
3.
go back to reference De Waele JJ, Lipman J, Akova M, Bassetti M, Dimopoulos G, Kaukonen M, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Udy AA, Starr T, Wallis SC, Roberts JA (2014) Risk factors for target non-attainment during empirical treatment with beta-lactam antibiotics in critically ill patients. Intensive Care Med 40:1340–1351CrossRefPubMed De Waele JJ, Lipman J, Akova M, Bassetti M, Dimopoulos G, Kaukonen M, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Udy AA, Starr T, Wallis SC, Roberts JA (2014) Risk factors for target non-attainment during empirical treatment with beta-lactam antibiotics in critically ill patients. Intensive Care Med 40:1340–1351CrossRefPubMed
4.
go back to reference Huttner A, Harbarth S, Hope WW, Lipman J, Roberts JA (2015) Therapeutic drug monitoring of the beta-lactam antibiotics: what is the evidence and which patients should we be using it for? J Antimicrob Chemother 70:3178–3183PubMed Huttner A, Harbarth S, Hope WW, Lipman J, Roberts JA (2015) Therapeutic drug monitoring of the beta-lactam antibiotics: what is the evidence and which patients should we be using it for? J Antimicrob Chemother 70:3178–3183PubMed
5.
go back to reference Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J; DALI Study (2014) DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58:1072–1083CrossRefPubMed Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J; DALI Study (2014) DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58:1072–1083CrossRefPubMed
6.
go back to reference Tabah A, De Waele J, Lipman J, Zahar JR, Cotta MO, Barton G, Timsit JF, Roberts JA; Working Group for Antimicrobial Use in the ICU within the Infection Section of the European Society of Intensive Care Medicine (ESICM) (2015) The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs. J Antimicrob Chemother 70:2671–2677CrossRefPubMed Tabah A, De Waele J, Lipman J, Zahar JR, Cotta MO, Barton G, Timsit JF, Roberts JA; Working Group for Antimicrobial Use in the ICU within the Infection Section of the European Society of Intensive Care Medicine (ESICM) (2015) The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs. J Antimicrob Chemother 70:2671–2677CrossRefPubMed
7.
go back to reference Cotta MO, Roberts JA, Lipman J (2015) Antibiotic dose optimization in critically ill patients. Med Intensiva 39:563–572CrossRefPubMed Cotta MO, Roberts JA, Lipman J (2015) Antibiotic dose optimization in critically ill patients. Med Intensiva 39:563–572CrossRefPubMed
8.
go back to reference Pea F, Viale P, Furlanut M (2005) Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 44:1009–1034CrossRefPubMed Pea F, Viale P, Furlanut M (2005) Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 44:1009–1034CrossRefPubMed
9.
go back to reference Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1–10CrossRefPubMed Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1–10CrossRefPubMed
10.
go back to reference De Waele J, Carlier M, Hoste E, Depuydt P, Decruyenaere J, Wallis SC, Lipman J, Roberts JA (2014) Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis. Minerva Anestesiol 80:1302–1309PubMed De Waele J, Carlier M, Hoste E, Depuydt P, Decruyenaere J, Wallis SC, Lipman J, Roberts JA (2014) Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis. Minerva Anestesiol 80:1302–1309PubMed
11.
go back to reference Abdul-Aziz MH, Sulaiman H, Mat-Nor MB, Rai V, Wong KK, Hasan MS, Abd Rahman AN, Jamal JA, Wallis SC, Lipman J, Staatz CE, Roberts JA (2016) Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Med 42:1535–1545. doi:10.1007/s00134-015-4188-0 CrossRefPubMed Abdul-Aziz MH, Sulaiman H, Mat-Nor MB, Rai V, Wong KK, Hasan MS, Abd Rahman AN, Jamal JA, Wallis SC, Lipman J, Staatz CE, Roberts JA (2016) Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Med 42:1535–1545. doi:10.​1007/​s00134-015-4188-0 CrossRefPubMed
12.
go back to reference Craig WA (2014) Editorial commentary: are blood concentrations enough for establishing pharmacokinetic/pharmacodynamic relationships? Clin Infect Dis 58:1084–1085CrossRefPubMed Craig WA (2014) Editorial commentary: are blood concentrations enough for establishing pharmacokinetic/pharmacodynamic relationships? Clin Infect Dis 58:1084–1085CrossRefPubMed
13.
go back to reference Du Bois D, Du Bois EF (1989) A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition 5:303–313PubMed Du Bois D, Du Bois EF (1989) A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition 5:303–313PubMed
14.
go back to reference Leclercq R, Cantón R, Brown DF, Giske CG, Heisig P, MacGowan AP, Mouton JW, Nordmann P, Rodloff AC, Rossolini GM, Soussy CJ, Steinbakk M, Winstanley TG, Kahlmeter G (2013) EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 19:141–160CrossRefPubMed Leclercq R, Cantón R, Brown DF, Giske CG, Heisig P, MacGowan AP, Mouton JW, Nordmann P, Rodloff AC, Rossolini GM, Soussy CJ, Steinbakk M, Winstanley TG, Kahlmeter G (2013) EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 19:141–160CrossRefPubMed
15.
go back to reference Hayashi Y, Roberts JA, Paterson DL, Lipman J (2010) Pharmacokinetic evaluation of piperacillin–tazobactam. Expert Opin Drug Metab Toxicol 6:1017–1031CrossRefPubMed Hayashi Y, Roberts JA, Paterson DL, Lipman J (2010) Pharmacokinetic evaluation of piperacillin–tazobactam. Expert Opin Drug Metab Toxicol 6:1017–1031CrossRefPubMed
16.
go back to reference Wong G, Briscoe S, Adnan S, McWhinney B, Ungerer J, Lipman J, Roberts JA (2013) Protein binding of beta-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? Antimicrob Agents Chemother 57:6165–6170CrossRefPubMedPubMedCentral Wong G, Briscoe S, Adnan S, McWhinney B, Ungerer J, Lipman J, Roberts JA (2013) Protein binding of beta-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? Antimicrob Agents Chemother 57:6165–6170CrossRefPubMedPubMedCentral
17.
go back to reference Patel KB, Nicolau DP, Nightingale CH, Quintiliani R (1995) Pharmacokinetics of cefotaxime in healthy volunteers and patients. Diagn Microbiol Infect Dis 22:49–55CrossRefPubMed Patel KB, Nicolau DP, Nightingale CH, Quintiliani R (1995) Pharmacokinetics of cefotaxime in healthy volunteers and patients. Diagn Microbiol Infect Dis 22:49–55CrossRefPubMed
21.
go back to reference European Centre for Disease Prevention and Control (ECDC) (2015) Antimicrobial resistance surveillance in Europe 2014. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). ECDC, Stockholm European Centre for Disease Prevention and Control (ECDC) (2015) Antimicrobial resistance surveillance in Europe 2014. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). ECDC, Stockholm
22.
go back to reference Kohner PC, Robberts FJL, Cockerill FR 3rd, Patel R (2009) Cephalosporin MIC distribution of extended-spectrum-β-lactamase- and pAmpC-producing Escherichia coli and Klebsiella species. J Clin Microbiol 47:2419–2425CrossRefPubMedPubMedCentral Kohner PC, Robberts FJL, Cockerill FR 3rd, Patel R (2009) Cephalosporin MIC distribution of extended-spectrum-β-lactamase- and pAmpC-producing Escherichia coli and Klebsiella species. J Clin Microbiol 47:2419–2425CrossRefPubMedPubMedCentral
23.
go back to reference Abdul-Aziz MH, Lipman J, Mouton JW, Hope WW, Roberts JA (2015) Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development. Semin Respir Crit Care Med 36:136–153CrossRefPubMed Abdul-Aziz MH, Lipman J, Mouton JW, Hope WW, Roberts JA (2015) Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development. Semin Respir Crit Care Med 36:136–153CrossRefPubMed
24.
go back to reference Tam VH, Schilling AN, Melnick DA, Coyle EA (2005) Comparison of beta-lactams in counter-selecting resistance of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 52:145–151CrossRefPubMed Tam VH, Schilling AN, Melnick DA, Coyle EA (2005) Comparison of beta-lactams in counter-selecting resistance of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 52:145–151CrossRefPubMed
25.
go back to reference Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH (2000) The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118:146–155CrossRefPubMed Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH (2000) The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118:146–155CrossRefPubMed
26.
go back to reference Scaglione F, Esposito S, Leone S, Lucini V, Pannacci M, Ma L, Drusano GL (2009) Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia. Eur Respir J 34:394–400CrossRefPubMed Scaglione F, Esposito S, Leone S, Lucini V, Pannacci M, Ma L, Drusano GL (2009) Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia. Eur Respir J 34:394–400CrossRefPubMed
27.
go back to reference Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney BC, Ungerer JP, Lipman J, Roberts JA (2012) Subtherapeutic initial beta-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 142:30–39CrossRefPubMed Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney BC, Ungerer JP, Lipman J, Roberts JA (2012) Subtherapeutic initial beta-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 142:30–39CrossRefPubMed
28.
go back to reference Blot S, Lipman J, Roberts DM, Roberts JA (2014) The influence of acute kidney injury on antimicrobial dosing in critically ill patients: are dose reductions always necessary? Diagn Microbiol Infect Dis 79:77–84CrossRefPubMed Blot S, Lipman J, Roberts DM, Roberts JA (2014) The influence of acute kidney injury on antimicrobial dosing in critically ill patients: are dose reductions always necessary? Diagn Microbiol Infect Dis 79:77–84CrossRefPubMed
29.
go back to reference Carlier M, Carrette S, Stove V, Verstraete AG, De Waele JJ (2014) Does consistent piperacillin dosing result in consistent therapeutic concentrations in critically ill patients? A longitudinal study over an entire antibiotic course. Int J Antimicrob Agents 43:470–473CrossRefPubMed Carlier M, Carrette S, Stove V, Verstraete AG, De Waele JJ (2014) Does consistent piperacillin dosing result in consistent therapeutic concentrations in critically ill patients? A longitudinal study over an entire antibiotic course. Int J Antimicrob Agents 43:470–473CrossRefPubMed
30.
go back to reference U.S. Department of Health and Human Services, Food and Drug Administration (FDA) (1998) Guidance for industry. Pharmacokinetics in patients with impaired renal function—study design, data analysis, and impact on dosing and labeling. FDA, Rockville, MD U.S. Department of Health and Human Services, Food and Drug Administration (FDA) (1998) Guidance for industry. Pharmacokinetics in patients with impaired renal function—study design, data analysis, and impact on dosing and labeling. FDA, Rockville, MD
31.
go back to reference Mouton JW, Touzw DJ, Horrevorts AM, Vinks AA (2000) Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet 39:185–201CrossRefPubMed Mouton JW, Touzw DJ, Horrevorts AM, Vinks AA (2000) Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet 39:185–201CrossRefPubMed
32.
go back to reference Dreetz M, Hamacher J, Eller J, Borner K, Koeppe P, Schaberg T, Lode H (1996) Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem–cilastatin. Antimicrob Agents Chemother 40:105–109PubMedPubMedCentral Dreetz M, Hamacher J, Eller J, Borner K, Koeppe P, Schaberg T, Lode H (1996) Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem–cilastatin. Antimicrob Agents Chemother 40:105–109PubMedPubMedCentral
Metadata
Title
High target attainment for β-lactam antibiotics in intensive care unit patients when actual minimum inhibitory concentrations are applied
Authors
H. Woksepp
A. Hällgren
S. Borgström
F. Kullberg
A. Wimmerstedt
A. Oscarsson
P. Nordlund
M-L. Lindholm
J. Bonnedahl
L. Brudin
B. Carlsson
T. Schön
Publication date
01-03-2017
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 3/2017
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-016-2832-4

Other articles of this Issue 3/2017

European Journal of Clinical Microbiology & Infectious Diseases 3/2017 Go to the issue